Physical Address
IGBB
Portera HPC Building
2 Research Boulevard
Starkville, MS 39759
Mailing Address
IGBB
Portera HPC Building
Box 9627
Mississippi State, MS 39762
Phone/Fax
Phone: 662-325-8278
Fax: 662-325-7692
We highly recommend that anyone wishing to contact the IGBB via the Internet/e-mail do so by submitting a HelpDesk ticket. Submitting a HelpDesk ticket ensures that your question is directed to the appropriate IGBB staff member(s) and is not left unanswered. In order to submit a HelpDesk ticket, you must first register for a free MyIGBB account. Registration is simple, takes less than a minute, and obligates you to absolutely nothing.
If you do not wish to use the IGBB HelpDesk, you may send an e-mail to one of the following IGBB employees: Dr. Olga Pechanova (Proteomics Lead), Dr. Chuan-Yu Hsu (Genomics Lead), Mr. Tony Arick (Computational Biology Lead), or Ms. Kelsey Stewart (Contract & Grant Specialist).
See Personnel for more contact names/numbers/e-mail addresses.
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
IGBB Authors:
Mariola J. EdelmannPUBLICATION YEAR:
2011IMPACT FACTOR:
7.093CITATION COUNT:
73Edelmann MJ, Nicholson B, Kessler BM (2011) Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.
Expert Reviews in Molecular Medicine 13: e35.
DOI:
10.1017/S1462399411002031EID:
2-s2.0-84857085837PMID: 22088887
DOWNLOAD PDFABSTRACTRecent advances in the development and discovery of pharmacological interventions within the ubiquitin-proteasome system (UPS) have uncovered an enormous potential for possible novel treatments of neurodegenerative disease, cancer, immunological disorder and microbial infection. Interference with proteasome activity, although initially considered unlikely to be exploitable clinically, has already proved to be very effective against haematological malignancies, and more specific derivatives that target subsets of proteasomes are emerging. Recent small-molecule screens have revealed inhibitors against ubiquitin-conjugating and -deconjugating enzymes, many of which have been evaluated for their potential use as therapeutics, either as single agents or in synergy with other drugs. Here, we discuss recent advances in the characterisation of novel UPS modulators (in particular, inhibitors of ubiquitin-conjugating and -deconjugating enzymes) and how they pave the way towards new therapeutic approaches for the treatment of proteotoxic disease, cancer and microbial infection.
Dr. Andy PerkinsAssociate Professor
Computer Science & EngineeringIGBB Affiliate
email(662) 325-0004
website
The IGBB is supported, in part, by the following units:
The IGBB is an HPC² member center.
